Literature DB >> 9613508

MR of leptomeningeal spinal and posterior fossa amyloid.

S Horowitz1, C Thomas, G Gruener, S Nand, J F Shea.   

Abstract

We report an unusual cause of leptomeningeal MR enhancement, amyloid, along the surfaces of the spinal cord and brain stem and in the spinal subarachnoid space, with sacral intradural and epidural deposition. Type I familial amyloid polyneuropathy may cause amyloid deposition along the leptomeninges of the spinal cord and brain in addition to the visceral organs and the peripheral somatic and autonomic nerves.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9613508      PMCID: PMC8337585     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  4 in total

1.  Rostrocaudal dynamics of CSF biomarkers.

Authors:  Andrew Tarnaris; Ahmed K Toma; Miles D Chapman; Axel Petzold; Geoff Keir; Neil D Kitchen; Laurence D Watkins
Journal:  Neurochem Res       Date:  2010-12-30       Impact factor: 3.996

2.  Transthyretin-related familial amyloid polyneuropathy: evaluation of CSF enhancement on serial T1-weighted and fluid-attenuated inversion recovery images following intravenous contrast administration.

Authors:  Toshinori Hirai; Yukio Ando; Masayuki Yamura; Mika Kitajima; Yoshiko Hayashida; Yukunori Korogi; Taro Yamashita; Yasuyuki Yamashita
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

3.  Familial amyloid polyneuropathy: hypertrophy of ligaments supporting the spinal cord.

Authors:  Mika Kitajima; Yukunori Korogi; Masayuki Yamura; Ichiro Ikushima; Yoshiko Hayashida; Yukio Ando; Makoto Uchino; Yasuyuki Yamashita
Journal:  AJNR Am J Neuroradiol       Date:  2004-10       Impact factor: 3.825

4.  Oculoleptomeningeal Amyloidosis associated with transthyretin Leu12Pro in an African patient.

Authors:  P McColgan; S Viegas; S Gandhi; K Bull; R Tudor; F Sheikh; J Pinney; M Fontana; D Rowczenio; J D Gillmore; J A Gilbertson; C J Whelan; S Shah; Z Jaunmuktane; J L Holton; J M Schott; D J Werring; P N Hawkins; M M Reilly
Journal:  J Neurol       Date:  2014-12-09       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.